<DOC>
	<DOCNO>NCT00596830</DOCNO>
	<brief_summary>Determine whether addition CP- 751,871 combination paclitaxel plus carboplatin prolongs survival patient locally advance ( Stage IIIB pleural effusion ) metastatic ( Stage IV recurrent ) NSCLC non adenocarcinoma histology .</brief_summary>
	<brief_title>Carboplatin And Paclitaxel With Or Without CP-751 , 871 ( An IGF-1R Inhibitor ) For Advanced NSCLC Of Squamous , Large Cell And Adenosquamous Carcinoma Histology</brief_title>
	<detailed_description>The study discontinue December 29 , 2009 due analysis independent Data Safety Monitoring Committee indicate addition CP-751,871 [ figitumumab ] paclitaxel plus carboplatin would unlikely meet primary endpoint improve overall survival compare paclitaxel plus carboplatin alone . The DSMC recommendation terminate trial base futility , specific safety concern ; however , DSMC recommend investigate hyperglycemia potential contributor morbidity patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Large Cell</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Confirmed diagnosis non small cell lung cancer primary histology predominantly squamous cell , large cell adenosquamous carcinoma . Advanced NSCLC document Stage IIIB ( pleural effusion ) Stage IV recurrent disease . No prior systemic treatment NSCLC , except adjuvant chemotherapy . Adjuvant chemotherapy must complete great equal 12 month prior randomization . Prior surgery radiation therapy permit complete least 3 week prior randomization acute toxicity resolve . ECOG performance status ( PS ) 0 1 . Patients symptomatic central nervous system ( CNS ) metastases permitted . Patients require chronic steroid use patient uncontrolled diabetes permit . Patients active cancer type permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>IGF-1R inhibitor</keyword>
	<keyword>Non-small-cell lung carcinoma</keyword>
	<keyword>CP-751</keyword>
	<keyword>871</keyword>
</DOC>